Skip to Content
Merck
CN
  • Short pulse laser induces less inflammatory cytokines in the murine retina after laser photocoagulation.

Short pulse laser induces less inflammatory cytokines in the murine retina after laser photocoagulation.

Ophthalmic research (2015-01-13)
Aiko Ito, Yoshio Hirano, Miho Nozaki, Masayuki Ashikari, Kazuhiko Sugitani, Yuichiro Ogura
ABSTRACT

The purpose of this study was to evaluate the effect of pulse duration on the expression of inflammatory cytokines in the murine retina after laser photocoagulation treatment with a PASCAL(®) pattern scan laser photocoagulator and conventional laser treatment. Retinal scatter laser photocoagulation was performed on C57BL/6J mice using a short pulse (10 ms) with a PASCAL laser or conventional settings (100 ms) with a multicolor laser. Eyes were enucleated before treatment (control) and 1 day, 3 days and 7 days after treatment. The levels of inflammatory cytokines (i.e., VEGF, MCP-1, RANTES and IL-6) in the retina/choroid were quantified by an ELISA. The expression patterns of VEGF and macrophages (i.e., F4/80) in the retina/choroid were evaluated by immunohistochemistry. The levels of RANTES, IL-6 and MCP-1 after PASCAL and conventional laser treatments were significantly elevated compared with controls (p < 0.05). Conventional laser treatment, but not PASCAL treatment, resulted in the up-regulation of VEGF. RANTES and IL-6 levels on day 1 and MCP-1 levels on day 3 in the sensory retina were also significantly up-regulated with conventional laser treatment compared with PASCAL treatment (p < 0.05). Immunohistochemical analysis showed that PASCAL treatment was associated with lower VEGF and F4/80 expression levels compared with conventional laser treatment. Our data suggested that the short pulse duration induced fewer inflammatory cytokines in the sensory retina compared with the conventional pulse duration. Short pulse laser photocoagulation with the PASCAL may prevent macular edema after panretinal photocoagulation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, BioUltra, ≥99.0% (T)
Sigma-Aldrich
Imidazole, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
Imidazole, BioUltra, Molecular Biology, ≥99.5% (GC)
Sigma-Aldrich
Imidazole, puriss. p.a., ≥99.5% (GC)
Sigma-Aldrich
Imidazole, ReagentPlus®, 99%
Sigma-Aldrich
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, BioXtra, ≥97 .0%
Sigma-Aldrich
Imidazole, ≥99% (titration), crystalline
Sigma-Aldrich
Imidazole, Molecular Biology, ≥99% (titration)
Sigma-Aldrich
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, ≥97.0%
Sigma-Aldrich
Imidazole, ACS reagent, ≥99% (titration)
Sigma-Aldrich
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, Molecular Biology, ≥97.0%
USP
Imidazole, United States Pharmacopeia (USP) Reference Standard
Imidazole, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Imidazole, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
Sigma-Aldrich
Imidazole, ReagentPlus®, 99%, Redi-Dri, free-flowing
Sigma-Aldrich
Imidazole, Molecular Biology, ≥99% (titration), free-flowing, Redi-Dri
Ondansetron impurity E, European Pharmacopoeia (EP) Reference Standard
Supelco
Imidazole, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Imidazole, Vetec, reagent grade, 98%
Sigma-Aldrich
Sodium fluoride 0.5 M solution
Sigma-Aldrich
Amyl alcohol, ≥99%, FG
Sigma-Aldrich
Imidazole buffer Solution, BioUltra, 1 M in H2O
Supelco
1-Pentanol, analytical standard
Sigma-Aldrich
Ethylenediaminetetraacetic acid disodium salt solution, BioUltra, pH 8.0, ~0.5 M in H2O
Supelco
Fluoride ion solution for ISE, 0.1 M F-, for ion-selective electrodes
Sigma-Aldrich
Ethylenediaminetetraacetic acid, BioUltra, ≥99.0% (KT)
Sigma-Aldrich
Ethylenediaminetetraacetic acid, ≥98.0% (KT)
Sigma-Aldrich
Sodium fluoride, anhydrous, powder, 99.99% trace metals basis
Sigma-Aldrich
Ethylenediaminetetraacetic acid, 99.995% trace metals basis
Sigma-Aldrich
1-Pentanol, ACS reagent, ≥99%